---
title: "FDA Grants Accelerated Approval to Etcamah for ESR1-Mutant HR+/HER2− Advanced Breast Cancer"
id: "fda-news-releases-1-fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment"
canonical_url: "https://medichelpline.com/clinical-feed/fda-news-releases-1-fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "FDA News Releases"
source_url: "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment"
published_at: "2026-09-04T19:38:04.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA Grants Accelerated Approval to Etcamah for ESR1-Mutant HR+/HER2− Advanced Breast Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/fda-news-releases-1-fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** FDA News Releases
- **Source URL:** [Original Journal Publication](http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment)
- **Published At:** 2026-09-04T19:38:04.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- The FDA granted **accelerated approval** to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adults with hormone receptor–positive, HER2‑negative locally advanced or metastatic breast cancer when an **ESR1** resistance mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy, using an FDA‑authorized test. - The approval is contingent on confirmatory trials because the approval was based on a surrogate/intermediate endpoint rather than a demonstrated long‑term clinical benefit. - The decision represents the first FDA approval of a cancer therapy guided by detection of a resistance mutation in circulating tumor DNA (**ctDNA**) before radiographic progression is evident. - Efficacy was evaluated in a trial comparing switching to Etcamah plus a CDK4/6 inhibitor versus continuing an aromatase inhibitor plus a CDK4/6 inhibitor; estimated median **progression‑free survival** was 16 months for the Etcamah arm and 9.2 months for the aromatase inhibitor arm. - The FDA authorized the Guardant360 CDx assay as the companion diagnostic to identify patients with **ESR1** mutations for Etcamah treatment. - The prescribing information includes a boxed warning for risk of irregular heart rhythm when Etcamah is coadministered with certain drugs, plus warnings for bradycardia and potential fetal harm. - The accelerated approval was granted to AstraZeneca following review and an Oncologic Drugs Advisory Committee meeting on April 30, 2026; full prescribing information will be posted on Drugs@FDA. - At initial diagnosis of HR‑positive metastatic breast cancer, fewer than 5% of patients have an **ESR1** mutation; after progression on aromatase inhibitors, nearly 40% will have acquired this mutation, underscoring its role in acquired endocrine resistance. - The FDA based the accelerated approval on measurement of the time patients lived without disease worsening from the point the resistance mutation was first detected in blood; the agency required confirmatory studies to verify clinical benefit.
## Clinical Analysis & Structured Key Points
* [Skip to main content](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment#main-content) * [Skip to FDA Search](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment#search-form) * [Skip to in this section menu](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment#section-nav) * [Skip to footer links](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment#footer) ![U.S. flag](https://www.fda.gov/themes/custom/preview/assets/images/US_Flag.png) An official website of the United States government [Here’s how you know ](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment) ![Dot gov](https://www.fda.gov/themes/custom/preview/assets/images/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. ![SSL](https://www.fda.gov/themes/custom/preview/assets/images/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![U.S. Food and Drug Administration logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg) ](https://www.fda.gov/ "FDA Homepage") * Search * Menu Search FDA Submit search ## Featured * [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=referral&utm_source=fda_gov_menu "Report a Problem with an FDA Regulated Product") * [Contact FDA](https://www.fda.gov/about-fda/contact-fda) * [FDA Guidance Documents](https://www.fda.gov/regulatory-information/search-fda-guidance-documents) * [Recalls, Market Withdrawals and Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts) * [Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements) * [Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) * [Advisory Committees](https://www.fda.gov/advisory-committees) * [En Español](https://www.fda.gov/fda-en-espanol) ## Products * [Food](https://www.fda.gov/food) * [Drugs](https://www.fda.gov/drugs) * [Medical Devices](https://www.fda.gov/medical-devices) * [Radiation-Emitting Products](https://www.fda.gov/radiation-emitting-products) * [Vaccines, Blood, and Biologics](https://www.fda.gov/vaccines-blood-biologics) * [Animal and Veterinary](https://www.fda.gov/animal-veterinary) * [Cosmetics](https://www.fda.gov/cosmetics) * [Tobacco Products](https://www.fda.gov/tobacco-products) ## Topics * [About FDA](https://www.fda.gov/about-fda) * [Combination Products](https://www.fda.gov/combination-products) * [Regulatory Information](https://www.fda.gov/regulatory-information) * [Safety](https://www.fda.gov/safety) * [Emergency Preparedness](https://www.fda.gov/emergency-preparedness-and-response) * [International Programs](https://www.fda.gov/international-programs) * [News and Events](https://www.fda.gov/news-events) * [Training and Continuing Education](https://www.fda.gov/training-and-continuing-education) * [Inspections and Compliance](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations) * [Science and Research](https://www.fda.gov/science-research) ## Information For * [Consumers](https://www.fda.gov/consumers) * [Patients](https://www.fda.gov/patients) * [Industry](https://www.fda.gov/industry) * [Health Professionals](https://www.fda.gov/health-professionals) * [Federal, State and Local Officials](https://www.fda.gov/federal-state-local-tribal-and-territorial-officials) 1. [Home](https://www.fda.gov/) 2. [News & Events](https://www.fda.gov/news-events) 3. [FDA Newsroom](https://www.fda.gov/news-events/fda-newsroom) 4. [Press Announcements](https://www.fda.gov/news-events/fda-newsroom/press-announcements) 5. FDA Grants Accelerated Approval to a New Breast Cancer Treatment 1. [ Press Announcements ](https://www.fda.gov/news-events/fda-newsroom/press-announcements "Press Announcements") [In this section](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment#section-nav) * [ Press Announcements ](https://www.fda.gov/news-events/fda-newsroom/press-announcements "Press Announcements") FDA News Release # FDA Grants Accelerated Approval to a New Breast Cancer Treatment [ More Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements) For Immediate Release: September 04, 2026 The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them. FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (_ESR1_) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test. _ESR1_ mutations are acquired resistance mutations that a tumor may develop during treatment with an aromatase inhibitor, a type of endocrine therapy that is a common front-line treatment for locally advanced or metastatic breast cancer. At the diagnosis of HR-positive metastatic breast cancer, fewer than 5 percent of patients will have this tumor mutation. After disease progression on an aromatase inhibitor, nearly 40 percent of patients will have this tumor mutation. “Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment. We owe them every weapon in our arsenal.” **said Acting FDA Commissioner Kyle Diamantas, J.D.** “Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.” The accelerated approval program allows for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on surrogate or intermediate endpoints. In this case, accelerated approval of Etcamah was granted based on how long patients lived without their disease worsening, measured from the point when the resistance mutation was first detected in the blood. Since it is not yet confirmed whether intervening at this point, rather than at the time of confirmed disease progression, translates into a clinically meaningful benefit, the FDA has required confirmatory studies to verify and describe clinical benefit. “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval,” **said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence**. “This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing. But additional evidence is needed to confirm clinical benefit.” ctDNA is made up of tiny pieces of tumor DNA released into the blood, which can allow for earlier molecular detection of resistance mutations. To ensure precise patient matching, the FDA also authorized the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with _ESR1_ mutations for treatment with camizestrant. Efficacy was evaluated in a clinical trial to assess switching to Etcamah, an oral tablet, in combination with a CDK4/6 inhibitor versus continuing an aromatase inhibitor in combination with a CDK4/6 inhibitor. Estimated median progression-free survival was 16 months in the Etcamah and CDK4/6 inhibitor arm and 9.2 months in the aromatase inhibitor and CDK4/6 inhibitor arm. The prescribing information includes a boxed warning for the risk of irregular heart rhythm when Etcamah is taken together with certain other medications, as well as warnings and precautions for an abnormally slow heart rate and potential harm to an unborn baby. Full prescribing information for Etcamah will be posted on Drugs@FDA. On April 30, 2026, the FDA convened the [Oncologic Drugs Advisory Committee](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026 "April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - 04/30/2026") for this application. The accelerated approval was granted to AstraZeneca. * * * **Media:** [FDA Request for Comment](https://www.hhs.gov/request-for-comment-form/index.html?Agency=FDA) 202-690-6343 **Consumer:** 888-INFO-FDA ### Boilerplate The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. * * * * ## Content current as of: 09/04/2026 * ## Regulated Product(s) * Drugs * ## Follow FDA * [ Follow @US_FDA on X ](https://x.com/FDA)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) * [Follow FDA on Facebook](https://www.facebook.com/FDA)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) * [ Follow @FDAMedia on X ](https://x.com/FDAMedia)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) ## Feedback form ### Success Thank you. Your feedback has been received. ### Error alert message Was this page helpful? * Yes No Submit ![U.S. flag](https://touchpoints.app.cloud.gov/img/us_flag_small.png) An official form of the United States government. Provided by [Touchpoints](https://touchpoints.digital.gov) Feedback * [FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive) * [About FDA](https://www.fda.gov/about-fda) * [Accessibility](https://www.fda.gov/about-fda/about-website/internet-accessibility) * [Visitor Information](https://www.fda.gov/about-fda/visitor-information) * [Website Policies / Privacy](https://www.fda.gov/about-fda/about-website/website-policies) * [No FEAR Act](https://www.fda.gov/about-fda/jobs-and-training-fda/no-fear-act) * [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) * [FOIA](https://www.fda.gov/regulatory-information/freedom-information "Freedom of Information Act") * [HHS.gov](https://www.hhs.gov/ "Health and Human Services") * [USA.gov](https://www.usa.gov/) [Contact FDA](https://www.fda.gov/about-fda/contact-fda) [ Follow FDA on Facebook ](https://www.facebook.com/FDA "Follow FDA on Facebook") [ Follow FDA on X ](https://x.com/FDA "Follow FDA on X") [ Follow FDA on Instagram ](https://instagram.com/FDA "Follow FDA on Instagram") [ Follow FDA on LinkedIn ](https://www.linkedin.com/company/fda/ "Follow FDA on LinkedIn") [ View FDA videos on YouTube ](https://youtube.com/@US_FDA "View FDA videos on YouTube") [ Subscribe to FDA RSS feeds ](https://www.fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds "Subscribe to FDA RSS feeds") [ ![Food and Drug Administration Logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg) ](https://www.fda.gov/ "FDA Homepage") Contact Number 1-888-INFO-FDA (1-888-463-6332) [Back to Top](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment) ![U.S. Department of Health and Human Services logo](https://cg-1b082c1b-3db7-477f-9ca5-bd51a786b41e.s3-us-gov-west-1.amazonaws.com/uploads/form/logo/6295/tag_FDA_logo\(2\).png) ## FDA.gov Site Customer Feedback Help us improve FDA.gov! We will use your responses to improve the experience for millions of people who visit FDA.gov. A red asterisk (*) indicates a required field. ### Success Thank you. Your feedback has been received. ### Error alert message 1. Which of the following best categorizes the information you were looking for on FDA.gov today? * Select one Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & Veterinary Cosmetics Tobacco Products Other 2. Which of the following best describes the information you were looking for on FDA.gov today? * Select one Recall or foodborne illness outbreak information Warning letters or enforcement actions Report a problem (adverse event) with a product Dispose of drugs or sharps Product approvals Drug labels Side effects of a product Contact an FDA office or staff member Complete or check registration for a product or facility Get FDA organizational information Import or export a product (including Prior Notice) Get a job with FDA Get training Get a form Comment on a proposed guidance or rule Check a regulation, rule, or guidance (for regulated industry) COVID-19 information Advice/information about a medical device, drug, food, or other FDA-regulated product Other 3. Did you find the information you were looking for on FDA.gov today? * Yes Partially. I found some of the information I was looking for. No I'm still looking 4. For this visit to the FDA site, which of the following roles best describes you? If you are a consultant or an attorney, please select the role of the individual or organization that you represent. * Select one Consumer, patient, or patient’s caregiver Regulated industry or business Healthcare professional (includes physician, nurse, physician’s assistant, nurse practitioner, or pharmacist) Public health/Policy professional Scientist, researcher Educator, professor, teacher, or student Media/Journalist FDA Employee/Contractors Other 5. How frequently do you visit FDA.gov? * This is my first time About once a year A couple of times a year Monthly Weekly Daily 6. On a scale from 0-10, based on your experience today, how likely are you to recommend this website to a friend or colleague? * 0 1 2 3 4 5 6 7 8 9 10 7) Overall, how satisfied or dissatisfied were you with your experience on the FDA website today? Navigation * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Look & Feel * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Using FDA’s search feature * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Understandability of the content * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Overall Experience * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Submit ![U.S. flag](https://touchpoints.app.cloud.gov/img/us_flag_small.png) An official form of the United States government. Provided by [Touchpoints](https://touchpoints.digital.gov) OMB Approval #0910-0360 · Expiration Date 07/08/2026 *[*]: required
## Related Clinical Research

- [Cancer screening and long-term care facilities: gaps highlighted by a missed breast cancer diagnos](https://medichelpline.com/clinical-feed/stat-news-3-opinion-cancer-screening-guidelines-need-to-address-long-term-care-facilities.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Higher dietary antioxidants linked to lower odds of cervical cancer in NHANES analysis](https://medichelpline.com/clinical-feed/medical-news-today-1-study-finds-link-between-antioxidant-rich-diets-and-lower-cervical-cancer-odds.md)
- [Wait times for adjuvant breast radiotherapy at Christchurch Hospital and COVID-19 effects](https://medichelpline.com/clinical-feed/pubmed-42594364.md) (DOI: 10.26635/6965.7269)
- [Individual-Level Trends in Mammography Screening, 2010–2023: All-Payer Vermont Claims Analysis](https://medichelpline.com/clinical-feed/pubmed-42240455.md) (DOI: 10.1158/1055-9965.EPI-26-0082)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.